Does hypertension confer a hypercoagulable state in stroke-prone spontaneously hypertensive rats?

Journal of Hypertension

Volumn 18, Issue 7, 2000, Pages 901-909

  Abumiya, Takeo ^a   Sakata, Toshiyuki ^a   Enjyoji, Kei Ichi ^a   Kato, Hisao ^a   Kawai, Jun ^b   Suzuki, Tsuneyuki ^b   Masuda, Junichi ^c   Sasaguri, Toshiyuki ^a   Ogata, Jun ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SHIMANE UNIVERSITY   (Japan)

Author keywords

Blood coagulation; C1 inhibitor; Factor Xa; Hypertension; Stroke prone spontaneously hypertensive rats

Indexed keywords

ANTITHROMBIN; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 10A; COMPLEMENT COMPONENT C1S INHIBITOR; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; FIBRINOGEN DEGRADATION PRODUCT; PROTEIN C; PROTHROMBIN; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CONTROLLED STUDY; HYPERCOAGULABILITY; HYPERTENSION; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PLASMA; PRIORITY JOURNAL; PROTHROMBIN TIME; RAT; STROKE;

EID: 0033910299     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200018070-00012     Document Type: Article

References (49)

1. 1 Lip GY, Li-Saw-Hee FL. Does hypertension confer a hypercoagulable state? J Hypertens 1998; 16:913-916.
2. 2 Cushman M, Yanez D, Psaty BM, Fried LP, Heiss G, Lee M, et al. Association of fibrinogen and coagulation factors VII and VIII with cardiovascular risk factors in the elderly: the Cardiovascular Health Study. Am J Epidemiol 1996; 143:665-676.
3. 3 Ishikawa S, Kario K, Nago N, Kayaba K, Hiraoka J, Matsuo H, et al. Factor VII and fibrinogen levels examined by age, sex, and other atherosclerotic risk factors in a Japanese population. The Jichi Medical School Cohort Study. Thromb Haemost 1997; 77:890-893.
4. 4 Blann AD, Naqvi T, Waite M, McCollum CN. von Willebrand factor and endothelial damage in essential hypertension. J Hum Hypertens 1993; 7:107-111.
5. 5 Junker R, Heinrich J, Schulte H, Erren M, Assmann G. Hemostasis in normotensive and hypertensive men: results of the PROCAM study. J Hypertens 1998; 16:917-923.
6. 6 Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med 1990; 227:273-278.
7. 7 Lemne C, De Faire U. Elevation of plasminogen activator inhibitor 1 in borderline hypertension is linked to concomitant metabolic disturbances. Eur J Clin Invest 1996; 26:692-697.
8. 8 Phillips GB, Jing TY, Resnick LM, Barbagallo M, Laragh JH, Sealey JE. Sex hormones and hemostatic risk factors for coronary heart disease in men with hypertension. J Hypertens 1993; 11:699-702.
9. 9 Lee AJ, Fowkes GR, Lowe GD, Rumley A. Determinants of fibrin D-dimer in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol 1995; 15:1094-1097.
10. 10 van Wersch JW. A chromogenic assay for coagulation factor VII: analytical performance characteristics and application in several diseases. Int J Clin Lab Res 1993; 23:221-224.
11. 11 Ogata J, Fujishima M, Tamaki K, Nakatomi Y, Ishitsuka T, Omae T. Strokeprone spontaneously hypertensive rats as an experimental model of malignant hypertension. A pathological study. Virchows Arch [A] 1982; 394:185-194.
12. 12 Abumiya T, Masuda J, Kawai J, Suzuki T, Ogata J. Heterogeneity in the appearance and distribution of macrophage subsets and their possible involvement in hypertensive vascular lesions in rats. Lab Invest 1996; 75:125-136.
13. 13 Enjyoji K, Miyazaki K, Kato H. Characterization of rat factors X and Xa: demonstration of factor Xa in rat plasma. J Biochem (Tokyo) 1991; 109:890-898.
14. 14 Prager NA, Abendschein DR, McKenzie CR, Eisenberg PR. Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots. Circulation 1995; 92:962-967.
15. 15 McKenzie CR, Abendschein DR, Eisenberg PR. Sustained inhibition of whole-blood clot procoagulant activity by inhibition of thrombus-associated factor Xa. Arterioscler Thromb Vasc Biol 1996; 16:1285-1291.
16. 16 Altieri DC, Edgington TS. Identification of effector cell protease receptor-1. A leukocyte-distributed receptor for the serine protease factor Xa. J Immunol 1990; 145:246-253.
17. 17 Altieri DC. Xa receptor EPR-1. FASEB J 1995; 9:860-865.
18. 18 Nicholson AC, Nachman RL, Altieri DC, Summers BD, Ruf W, Edgington TS, et al. Effector cell protease receptor-1 is a vascular receptor for coagulation factor Xa. J Biol Chem 1996; 271:28407-28413.
19. 19 Okamoto K, Yamori Y, Nagaoka A. Establishment of the stroke-prone spontaneously hypertensive rat (SHR). Circ Res 1974; 34 and 35:1143-1153.
20. 20 Kato H, Uchida K. Automated fluorogenic methods for the evaluation of the extrinsic coagulation reactions in human plasma. Thromb Res 1988; 50:77-90.
21. 21 Kokawa T, Abumiya T, Kimura T, Harada-Shiba M, Koh H, Tsushima M, et al. Tissue factor pathway inhibitor activity in human plasma. Measurement of lipoprotein-associated and free forms in hyperlipidemia. Arterioscler Thromb Vasc Biol 1995; 15:504-510.
22. 22 Miyata T, Zheng YZ, Sakata T, Tsushima N, Kato H. Three missense mutations in the protein C heavy chain causing type I and type II protein C deficiency. Thromb Haemost 1994; 71:32-37.
23. 23 Ellis V, Scully M, MacGregor I, Kakkar V. Inhibition of human factor Xa by various plasma protease inhibitors. Biochim Biophys Acta 1982; 701:24-31.
24. 24 Vicente V, Maia R, Alberca I, Tamagnini GP, Lopez Borrasca A. Congenital deficiency of vitamin K-dependent coagulation factors and protein C. Thromb Haemost 1984; 51:343-346.
25. 25 Prada AE, Zahedi K, Davis AE III. Regulation of C1 inhibitor synthesis. Immunobiology 1998; 199:377-388.
26. 26 van der Graaf F, Koedam JA, Bouma BN. Inactivation of kallikrein in human plasma. J Clin Invest 1983; 71:149-158.
27. 27 Pixley RA, Schapira M, Colman RW. The regulation of human factor XIIa by plasma proteinase inhibitors. J Biol Chem 1985; 260:1723-1729.
28. 28 Wuillemin WA, Minnema M, Meijers JC, Roem D, Eerenberg AJ, Nuijens JH, et al. Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for C1-inhibitor. Blood 1995; 85:1517-1526.
29. 29 Scherer RU, Giebler RM, Schmidt U, Paar D, Kox WJ. The influence of C1-esterase inhibitor substitution on coagulation and cardiorespiratory parameters in an endotoxin-induced rabbit model of hypercoagulability. Semin Thromb Hemost 1996; 22:357-366.
30. 30 Guerrero R, Velasco F, Rodriguez M, Lopez A, Rojas R, Alvarez MA, et al. Endotoxin-induced pulmonary dysfunction is prevented by C1-esterase inhibitor. J Clin Invest 1993; 91:2754-2760.
31. 31 Jansen PM, Eisele B, de Jong IW, Chang A, Delvos U, Taylor FB Jr, et al. Effect of C1 inhibitor on inflammatory and physiologic response patterns in primates suffering from lethal septic shock. J Immunol 1998; 160:475-484.
32. 32 Eldering E, Huijbregts CC, Lubbers YT, Longstaff C, Hack CE. Characterization of recombinant C1 inhibitor P1 variants. J Biol Chem 1992; 267:7013-7020.
33. 33 Djie MZ, Le Bonniec BF, Hopkins PC, Hipler K, Stone SR. Role of the P2 residue in determining the specificity of serpins. Biochemistry 1996; 35:11461-11469.
34. 34 Olson ST, Stephens AW, Hirs CH, Bock PE, Bjork I. Kinetic characterization of the proteinase binding defect in a reactive site variant of the serpin, antithrombin. Role of the P1′ residue in transition-state stabilization of antithrombin-proteinase complex formation. J Biol Chem 1995; 270:9717-9724.
35. 35 Hopkins PC, Crowther DC, Carrell RW, Stone SR. Development of a novel recombinant serpin with potential antithrombotic properties. J Biol Chem 1995; 270:11866-11871.
36. 36 Russell JA, Whaley K, Heaphy S. The sequence of a cDNA encoding functional murine C1-inhibitor protein. Biochim Biophys Acta 1997; 1352:156-160.
37. 37 Salvesen GS, Catanese JJ, Kress LF, Travis J. Primary structure of the reactive site of human C1-inhibitor. J Biol Chem 1985; 260:2432-2436.
38. 38 Zuraw BL, Lotz M. Regulation of the hepatic synthesis of C1 inhibitor by the hepatocyte stimulating factors interleukin 6 and interferon gamma. J Biol Chem 1990; 265:12664-12670.
39. 39 Katz Y, Strunk RC. Synthesis and regulation of C1 inhibitor in human skin fibroblasts. J Immunol 1989; 142:2041-2045.
40. 40 Lotz M, Zuraw BL. Interferon-gamma is a major regulator of C1-inhibitor synthesis by human blood monocytes. J Immunol 1987; 139:3382-3387.
41. 41 Schmaier AH, Murray SC, Heda GD, Farber A, Kuo A, McCrae K, et al. Synthesis and expression of C1 inhibitor by human umbilical vein endothelial cells. J Biol Chem 1989; 264:18173-18179.
42. 42 Schwogler S, Odenthal M, Knittel T, Meyer zum Buschenfelde KH, Ramadori G. Fat-storing cells of the rat liver synthesize and secrete C1-esterase inhibitor; modulation by cytokines. Hepatology 1992; 16:794-802.
43. 43 de Smet BJ, de Boer JP, Agterberg J, Rigter G, Bleeker WK, Hack CE. Clearance of human native, proteinase-complexed, and proteolytically inactivated C1-inhibitor in rats. Blood 1993; 81:56-61.
44. 44 Schmidt B, Gyapay G, Valay M, Fust G. Human recombinant macrophage colony-stimulating factor (M-CSF) increases CI-esterase inhibitor (CI-INH) synthesis by human monocytes. Immunology 1991; 74:677-679.
45. 45 Zheng Y, Chen Z, Yan J. Study of the relationship between complement activation and vascular endothelial damage in pregnancy induced hypertension [Article in Chinese]. Chung Hua Fu Chan Ko Tsa Chih 1996; 31:152-155.
46. 46 Kristensen BO, Petersen GB. Association between coronary heart disease and the C3F-gene in essential hypertension. Circulation 1978; 58:622-625.
47. 47 Schaadt O, Sorensen H, Krogsgaard AR. Association between the C3F-gene and essential hypertension. Clin Sci 1981; 61 (suppl 7):363s-365s.
48. 48 Dzielak DJ. The immune system and hypertension. Hypertension 1992; 19:136-144.
49. 49 Fu ML. Do immune system changes have a role in hypertension? J Hypertens 1995; 13:1259-1265.